Bristol-Myers gets 'potentially revolutionary medicine' in MyoKardia deal, CEO says

"MyoKardia is an important company because they developed a really interesting approach to the treatment of cardiovascular disease," Bristol-Myers Squibb CEO Giovanni Caforio said.

source https://www.cnbc.com/2020/10/05/bristol-myers-ceo-a-potentially-revolutionary-drug-in-myokardia-deal.html

Post a Comment

0 Comments